Abstract
A novel hydrophilic gold compound, tetrakis((trishydroxymethyl)phosphine)gold(I) chloride 1, has been investigated for its antitumor properties. In vitro studies demonstrate that 1 is active against HCT-15, AGS, PC-3, and LNCaP tumor cells. Cell cycle analysis of the HCT-15 cells by flow cytometry revealed elongation of the G1 phase of the cell cycle leading to growth inhibition. Administration of 1 to Balb/C mice inoculated with syngenic meth/A cells demonstrated statistically significant dose-dependent survival time.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology*
-
Cell Cycle / drug effects
-
Dose-Response Relationship, Drug
-
Flow Cytometry
-
Magnetic Resonance Spectroscopy
-
Mice
-
Mice, Inbred BALB C
-
Neoplasm Transplantation
-
Neoplasms, Experimental / mortality
-
Organogold Compounds
-
Organometallic Compounds / chemistry
-
Organometallic Compounds / pharmacology*
-
Phosphines / chemistry
-
Phosphines / pharmacology*
-
Tumor Cells, Cultured
Substances
-
Antineoplastic Agents
-
Organogold Compounds
-
Organometallic Compounds
-
Phosphines
-
tetrakis((trishydroxymethyl)phosphine)gold(I)